# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.sec.gov/Archives/edgar/data/1410098/000121390025094067/ea0258874-s3_cormedix.htm
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allo...
JMP Securities analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $22 price ta...
Planned Senior LeadershipThe following executives will form the core of the senior leadership team of the newly merged company ...
Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies e...